The use of BED and EUD concepts in heterogeneous radioactivity distributions on a multicellular scale for targeted radionuclide therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 1, 2007, Pages 143-150

  Kalogianni, Eleni ^a   Flux, Glenn D ^b   Malaroda, Alessandra ^b,c  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

BED; Dosimetry on multicellular scale; EUD; Nonuniform activity distribution; Survival fraction; Targeted radionuclide therapy

Indexed keywords

IODINE 131; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; YTTRIUM 90;

COMPUTER PROGRAM; CONFERENCE PAPER; DOSE CALCULATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG TARGETING; GEOMETRY; HISTOGRAM; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DETECTOR; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIODENSITOMETRY; RADIOISOTOPE THERAPY; SIMULATION; SURVIVAL; THERAPY EFFECT; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, RADIATION; RADIOISOTOPES; RADIOTHERAPY;

EID: 34247847867     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.308     Document Type: Conference Paper

References (15)

1. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986;27:1490.
2. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999;40(8):1337.
3. Zanzonico PB. Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments. J Nucl Med 1989;30:1036.
4. ICRU Report 67. Dose specification in nuclear medicine. J ICRU 2002;2:29.
5. Malaroda A, Flux G, Ott R. The application of dose-rate volume histograms and survival fractions to multicellular dosimetry. Cancer Biother Radiopharm 2005;20(1):58.
6. Malaroda A, Flux G, Ott R. Multicellular dosimetry in voxel geometry for targeted radionuclide therapy. Cancer Biother Radiopharm 2003;18:451.
7. Prestwich WV, Nunes J, Kwok CS. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med 1989;30(6):1036.
8. Howell RW, Goddu SM, Rao DV. Application of the linear-quatratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides. J Nucl Med 1994;35(11):1861.
9. Howell RW, Goddu SM, Rao DV. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. Med Phys 1998;25(1):37.
10. Sachs RK, Hahnfeld P, Brenners DJ. The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. Int J Radiat Biol 1997;72:351.
11. Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol 1991;64:242.
12. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20(1):47.
13. Niemierko A. Reporting and analysing dose distributions: a concept of equivalent uniform dose. Med Phys 1997;24:103.
14. Neti VSV, Howell RW. Log normal distribution of cellular uptake of radioactivity: Implications for biologic responses to radiopharmaceuticals. J Nucl Med 2006;47:1049.
15. Prideaux A, Song H, Ladenson P, et al. 3D-radiobiologic dosimetry (3D-RD): Patient-specific, 3-D dosimetry with radiobiologic modelling to evaluate treatment efficacy and toxicity. J Nucl Med 2006;47(Suppl.): 219P.